Validity and reliability of lung cancer quality of life Questionnaire from European Organization for Research and Treatment of Cancer (EORTC QLQ-LC13) in Iran

被引:0
|
作者
Motlagh, Karbasi M. [2 ]
Enjedani, E. [3 ]
Zamanian, H. [1 ]
Fathollahbeigy, F. [2 ]
Kiayee, N. [4 ]
Meybodi, Aghaie F. [5 ]
Beheshtee, M. [2 ]
机构
[1] Qom Univ Med Sci, Qom, Iran
[2] Univ Tehran Med Sci, Ctr Sci Res, Tehran, Iran
[3] Alzahra Univ, Tehran, Iran
[4] Univ Tehran, Tehran, Iran
[5] Univ Social Welf & Rehabil Sci, Tehran, Iran
来源
HEALTHMED | 2012年 / 6卷 / 06期
关键词
validity; reliability; lung cancer; quality of life; (EORTC QLQ LC13) questionnaire; TRANSLATION; QLQ-C30;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Lung Cancer has a great impact on different aspects of quality of life of patients who are diagnosed with such cancer; therefore, conducting research on such patient's quality of life is essential. In this study we will examine the effects of lung cancer on quality of life of patients who are diagnosed with this cancer and propose a suitable questionnaire for the purpose of determining various scopes of quality of life of patients as well as the validity and reliability of such questionnaire. Objective: The aim of this study is to investigation of validity and reliability of lung cancer quality of life from European Organization for Research and Treatment of Cancer (EORTC QLQ - LC13) in Iran. Method: 75 lung cancer patients admitted to hospitals in Iran cancer Institute of Tehran University of medical science and Masih daneshvari hospital were chosen by nonrandom sampling. Demographic questionnaire EORTC QLQ - LC13 and EORTC QLQ - C30 were completed by the questioner. Descriptive data by frequency tables were analyzed and content validity we used translation for translating and internal consistencies were measured by the Cranach's alpha coefficient. Results: total Cranach's alpha coefficient (The reliability or internal consistency) was 0.720. Spearman correlation coefficient of symptom and side effect subscale was 0.0601 not showed any overlap between questions of these subscales and the high measure of spearman rank correlation between symptom subscale and its questions was in the range of 0.357-0.754 and side effect subscale and its questions was 0.366-0.708, that indicated subscales of LC13 have significant correlation. Conclusion: In general, the findings of this study indicated that the Iranian version of the EORTC QLQ-LC13 is a reliable and valid supplementary measure of the quality of life in lung cancer patients and can be used in clinical trials and studies of outcome research in oncology.
引用
收藏
页码:2121 / 2124
页数:4
相关论文
共 50 条
  • [21] The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30): Validation of English version in Singapore
    N. Luo
    C. S. L. Fones
    S. E. Lim
    F. Xie
    J. Thumboo
    S. C. Li
    Quality of Life Research, 2005, 14 : 1181 - 1186
  • [22] The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30): Validation Study of the Thai Version
    Chatchawan Silpakit
    Suwanee Sirilerttrakul
    Manmana Jirajarus
    Thitiya Sirisinha
    Ekaphop Sirachainan
    Vorachai Ratanatharathorn
    Quality of Life Research, 2006, 15 : 167 - 172
  • [23] CROSS-CULTURAL APPLICATION OF THE EORTC QLQ-C30 AND QLQ-LC13: IMPACT OF SOCIAL EPIDEMIOLOGIC FACTORS ON QUALITY OF LIFE IN LUNG CANCER PATIENTS
    Ataman, F.
    Songur, N.
    Ay, S.
    Kaya, S.
    Bottomley, A.
    RADIOTHERAPY AND ONCOLOGY, 2008, 88 : S279 - S279
  • [24] Use of the Lung Cancer-Specific Quality of Life Questionnaire EORTC QLQ-LC13 in Clinical Trials: A Systematic Review of the Literature 20 Years After its Development
    Koller, Michael
    Warncke, Sophie
    Hjermstad, Marianne J.
    Arraras, Juan
    Pompili, Cecilia
    Harle, Amelie
    Johnson, Colin D.
    Chie, Wei-Chu
    Schulz, Christian
    Zeman, Florian
    van Meerbeeck, Jan P.
    Kulis, Dagmara
    Bottomley, Andrew
    CANCER, 2015, 121 (24) : 4300 - 4323
  • [25] The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for patients with Endometrial Cancer: EORTC QLQ-EN24
    Singer, Susanne
    Greimel, Elfriede
    QUALITY OF LIFE RESEARCH, 2010, 19 : 90 - 91
  • [26] Phase III development of the European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ) module for women undergoing breast reconstruction: The EORTC QLQ-BRR26
    Winters, Z. E.
    Balta, V.
    Thomson, H. J.
    Llewellyn-Bennett, R.
    Oberguggenberger, A.
    Sinove, Y.
    Nava, M.
    Bruno, N.
    Sandelin, K.
    Unukovych, D.
    Blondeel, P.
    Brandberg, Y.
    Johansson, H.
    CANCER RESEARCH, 2013, 73
  • [27] Independent psychometric validation of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Endometrial Cancer Module (EORTC QLQ-EN24)
    Stukan, M.
    Zalewski, K.
    Mardas, M.
    Filarska, D.
    Szajewski, M.
    Kmiec, A.
    Binkowska, P.
    Pietrzak-Stukan, M.
    Dudziak, M.
    Grabowski, J. P.
    Eskander, R. N.
    Greimel, E.
    EUROPEAN JOURNAL OF CANCER CARE, 2018, 27 (01)
  • [28] The European organization for research and treatment of cancer quality of life core questionnaire (EORTC QLQ-C30): Validation of English version in Singapore
    Xie, F
    Luo, N
    Li, SC
    VALUE IN HEALTH, 2004, 7 (03) : 252 - 252
  • [29] Cultural Adaptation and External Validation of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Thyroid Cancer (EORTC QLQ-THY34) in Colombia
    Gonzalez-Patino, Diego F.
    Zuniga, Sergio F.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2024, 239 (05) : S124 - S124
  • [30] The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30): translation and validation study of the Iranian version
    Montazeri, A
    Harirchi, I
    Vahdani, M
    Khaleghi, F
    Jarvandi, S
    Ebrahimi, M
    Haji-Mahmoodi, M
    SUPPORTIVE CARE IN CANCER, 1999, 7 (06) : 400 - 406